Exelixis, INC. (EXEL) — 8-K Filings

8-K Filings (12)

• 8-K Filing — Nov 7, 2025
• Exelixis Announces Executive and Director Changes — Aug 29, 2025 Risk: medium
  Exelixis, Inc. announced on August 29, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the d
• Exelixis Files 8-K on Shareholder Votes — Jun 2, 2025 Risk: low
  Exelixis, Inc. filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corporate action
• Exelixis Announces Board & Executive Changes — Mar 31, 2025 Risk: medium
  Exelixis, Inc. announced on March 31, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the departure of ce
• Exelixis Files 8-K: Other Events & Exhibits — Feb 21, 2025 Risk: low
  Exelixis, Inc. filed an 8-K on February 21, 2025, reporting events that occurred on February 20, 2025. The filing pertains to "Other Events" and "Financial Stat
• Exelixis, Inc. Files 8-K on Financials — Jan 13, 2025 Risk: low
  Exelixis, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing includes fina
• Exelixis, Inc. Files 8-K for Undisclosed Event — Oct 15, 2024 Risk: medium
  On October 14, 2024, Exelixis, Inc. filed an 8-K report to disclose an "Other Event." The filing does not contain specific details about the event itself, but i
• Exelixis Adds Two Directors to Board — Jun 3, 2024 Risk: low
  Exelixis, Inc. announced on May 30, 2024, the election of Dr. Michelle Werner and Mr. David R. Johnson to its Board of Directors, effective immediately. Dr. Wer
• Exelixis, Inc. Files 8-K Report — May 20, 2024 Risk: low
  On May 20, 2024, Exelixis, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." Specific details regar
• Exelixis Acquires Kairos Therapeutics for $400M Upfront — May 10, 2024 Risk: medium
  Exelixis, Inc. announced on May 9, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Kairos Therapeutics, Inc. for an u
• Exelixis Appoints New Chief Medical and Scientific Officers — Mar 29, 2024 Risk: medium
  Exelixis, Inc. announced on March 27, 2024, the appointment of Dr. Michelle Werner as Chief Medical Officer and Dr. Peter Lamb as Chief Scientific Officer. Dr.
• EXELIXIS 8-K: Financial Condition, Officer Comp, Exit Activities — Jan 8, 2024
  EXELIXIS, INC. filed an 8-K on January 8, 2024, reporting events that occurred on January 2, 2024. This filing indicates that the company is updating its public

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX